Another area of unmet need is understanding the clinical manifestation and management of SVT patients in the setting of an isolated JAK2 mutation or without elevated blood counts, as is the case with many patients who have JAK2 clonal hematopoiesis (CH) or an unclassifiable MPN (MPN-U). Here, JAK2 is linked to myeloproliferative neoplasm.